A survey of the current approaches to diagnosis and management of oral premalignant lesions

Journal of the American Dental Association

Volumn 138, Issue 12, 2007, Pages 1555-1562

  Epstein, Joel B ^a   Gorsky, Meir ^a,b   Fischer, Dena ^a   Gupta, Anurag ^a   Epstein, Matthew ^c   Elad, Sharon ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c Fred Hutchinson Cancer Research Center   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Diagnosis; Erythroplakia; Leukoplakia; Management; Oral premalignant lesions

Indexed keywords

EID: 37549056938     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2007.0104     Document Type: Article

References (45)

1. American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer Society; 2006.
2. Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers: the outcomes, the trends, the challenge. JADA 2001; 132(supplement):7S-11S.
3. National Cancer Institute. Surveillance, epidemiology, and end results program public-use data, 1973-1998. Rockville, Md.: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2001.
4. Shiboski CH, Shiboski SC, Silverman S Jr. Trends in oral cancer rates in the United States, 1973-1996. Community Dent Oral Epidemiol 2000;28(4):249-56.
5. Bouquot JE, Meckstroth RL. Oral cancer in a tobacco-chewing US population: no apparent increased incidence or mortality. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86(6):697-706.
6. Martin-Granizo R, Rodriguez-Campo F, Naval L, Diaz Gonzalez FJ. Squamous cell carcinoma of the oral cavity in patients younger than 40 years. Otolaryngol Head Neck Surg 1997;117(3 pt 1):268-75.
7. National Cancer Institute. Oral cancer (PDQ): Prevention. Available at: "www.cancer.gov.cancertopics/pdq/prevention/oral/healthprofessional/ allpages". Accessed Sept. 10, 2006.
8. Horowitz AM, Alfano MC. Perform a death-defying act: the 90-second oral cancer examination. JADA 2001;132(supplement):36S-40S.
9. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984; 53(3):563-8.
10. Gorsky M, Dayan D. Referral delay in diagnosis of oro/oropharyngeal cancer in Israel. Eur J Cancer B Oral Oncol 1995; 31B(3):166-8.
11. Gellrich NC, Suarez-Cunqueiro MM, Bremerich A, Schramm A. Characteristics of oral cancer in a central European population: defining the dentist's role. JADA 2003;134(3):307-14.
12. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46(4);518-39.
13. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003;14(1):47-62.
14. Epstein JB, Oakley C, Millner A, Emerton S, van der Meij E, Le N. The utility of toluidine blue application as a diagnostic aid in patients previously treated for upper oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83(5):537-47.
15. Epstein JB, Scully C, Spinelli J. Toluidine blue and Lugol's iodine application in the assessment of oral malignant disease and lesions at risk of malignancy. J Oral Pathol Med 1992;21(4):160-3.
16. Epstein JB, Feldman R, Dolor RJ, Porter SR. The utility of tolonium chloride rinse in the diagnosis of recurrent or second primary cancers in patients with prior upper aerodigestive tract cancer. Head Neck 2003;25(11):911-21.
17. Onofre MA, Sposto MR, Navarro CM. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(5):535-40.
18. Portugal LG, Wilson KM, Biddinger PW, Gluckman JL. The role of toluidine blue in assessing margin status after resection of squamous cell carcinomas of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1996;122(5):517-9.
19. Kerawala CJ, Beale V, Reed M, Martin IC. The role of vital tissue staining in the marginal control of oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2000;29(1):32-5.
20. Epstein JB, Zhang L, Poh C, Nakamura H, Berean K, Rosin M. Increased allelic loss in toluidine blue-positive oral premalignant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95(1): 45-50.
21. Zhang L, Williams M, Poh CF, et al. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res 2005;65(17):8017-21.
22. Epstein JB, Sciubba J, Silverman S Jr, Sroussi HY. Utility of toluidine blue in oral premalignant lesions and squamous cell carcinoma: continuing research and implications for clinical practice. Head Neck 2007;29(10):948-58.
23. Guo Z, Yamaguchi K, Sanchez-Cespedes M, Westra WH, Koch WM, Sidransky D. Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 2001;7(7):1963-8.
24. Sciubba JJ; for U.S. Collaborative OralCDx Study Group. Improving detection of precancerous and cancerous oral lesions: computer-assisted analysis of the oral brush biopsy. JADA 1999; 130(10):1445-57.
25. Scheifele C, Schmidt-Westhausen AM, Dietrich T, Reichart PA. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol 2004;40(8):824-8.
26. Pektas ZO, Keskin A, Günhan O, Karslio lu Y. Evaluation of nuclear morphometry and DNA ploidy status for detection of malignant and premalignant oral lesions: quantitative cytologic assessment and review of methods for cytomorphometric measurements. J Oral Maxillofac Surg 2006;64(4):628-35.
27. Poate TW, Buchanan JA, Hodgson TA, et al. An audit of the efficacy of the oral brush biopsy technique in a specialist oral medicine unit. Oral Oncol 2004;40(8):829-34.
28. Rick GM. Oral brush biopsy: the problem of false positives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96(3):252.
29. Potter TJ, Summerlin DJ, Campbell JH. Oral malignancies associated with negative transepithelial brush biopsy. J Oral Maxillofac Surg 2003;61(6):674-7.
30. Svirsky JA, Burns JC, Carpenter WM, et al. Comparison of computer-assisted brush biopsy results with follow up scalpel biopsy and histology. Gen Dent 2002;50(6):500-3.
31. Christian DC. Computer-assisted analysis of oral brush biopsies at an oral cancer screening program. JADA 2002;133(3):357-62.
32. Kerr AR, Sirois DA, Epstein JB. Clinical evaluation of chemiluminescent lighting: an adjunct for oral mucosal examinations. J Clin Dent 2006;17(3):59-63.
33. Epstein JB, Gorsky M, Lonky S, Silverman S Jr, Epstein JD, Bride M. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. Spec Care Dentist 2006;26(4):171-4.
34. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncology (in press).
35. Lane PM, Gilhuly T, Whitehead P, et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt 2006;11(2):024006.
36. Poh CF, Zhang L, Anderson DW, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 2006;12(22):6716-22.
37. De Veld DC, Witjes MJ, Sterenborg HJ, Roodenburg JL. The status of in vivo autofluorescence spectroscopy and imaging for oral oncology. Oral Oncol 2005;41(2):117-31.
38. Epstein JB, Gorsky M, Wong FL, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 1998;83(4):629-34.
39. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2004;(3): CD001829.
40. Gorsky M, Epstein JB. The effect of retinoids on premalignant oral lesions: focus on topical therapy. Cancer 2002;95(6):1258-64.
41. Zhang L, Poh CF, Lam WL, et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol 2001;37(6):505-12.
42. Epstein JB, Wan LS, Gorsky M, Zhang L. Oral lichen planus: progress in understanding its malignant potential and the implications for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003:96(1):32-7.
43. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336(13):897-904.
44. Demarosi F, Lodi G, Carrassi A, Soligo D, Sardella A. Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 2005;41(9):865-77.
45. Scheifelle C, Reichart PA, Hippler-Benscheidt M, Neuhaus P, Neuhaus R. Incidence of oral, pharyngeal, and laryngeal squamous cell carcinomas among 1515 patients after liver transplantation. Oral Oncol 2005;41(7):670-6.